Personalis Plunges 26.06% on Revenue Targets

On August 6, 2025, Personalis' stock experienced a significant drop of 26.06% in pre-market trading.

Personalis has set a revenue target of $70 million to $80 million for 2025, driven by a 59% sequential growth in clinical tests and an adjusted outlook for the biopharma sector. This ambitious target reflects the company's confidence in its ability to capitalize on the growing demand for precision oncology solutions.

In the second quarter of 2025, Personalis reported strong financial results, ending the quarter with $173.2 million in cash and no debt. This financial position provides the company with ample runway to fund its operations through reimbursement events, eliminating the need for immediate capital raises. The robust cash position underscores Personalis' financial stability and its ability to invest in future growth opportunities.